Addressing OUD treatment gaps and improving patient outcomes

In this portion of the Pharmaceutical Executive Video Interview, Joshua M. Cohen, MD, MPH, FAHS, Braeburn’s Chief Medical Officer, discusses how the study’s findings will contribute to closing treatment gaps and improving patient outcomes for patients suffering from fentanyl addiction, ensuring broader patient access to BRIXADI®, and more.